According to preclinical reports, AD transgenic mouse models showed decreased cortical BDNF expression as well as BDNF-mediated TrkB impairment of retrograde neuronal signal transport, whereas studies of serum BDNF levels in subjects with either severe AD or mild cognitive impairment reported conflicting results. This evidence concerns the gene NTRK2 and Alzheimer disease.